Regeneron Pharmaceuticals (REGN) Receives Analyst Rating

Regeneron Pharmaceuticals (REGN) : The consensus on Regeneron Pharmaceuticals (REGN) based on 18 analyst recommendation on the company stock is 2.39, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 2 which endorses a Buy on the stock. However, 6 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 1 analyst believes that the stock is a Buy, which can produce decent returns in the future. 10 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating. 1 analyst sees the stock overvalued at current levels and advises a Strong Sell on the stock.

Regeneron Pharmaceuticals (REGN) : The consensus price target for Regeneron Pharmaceuticals (REGN) is $475.19 for the short term with a standard deviation of $83.66. The most optimist securities analyst among the 16 who monitor the stock believes that the stock can reach $668, however, the pessimist price target for the company is $325.


Also, In a research note released to the investors, Baird downgrades its rating on Regeneron Pharmaceuticals (NASDAQ:REGN).The analysts at the brokerage house have a current rating of Neutral on the shares. Earlier, the shares were rated a Outperform by the brokerage firm. The rating by the firm was issued on August 5, 2016.

Regeneron Pharmaceuticals (NASDAQ:REGN): After opening at $396.56, the stock dipped to an intraday low of $394.87 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $404.98 and the buying power remained strong till the end. The stock closed at $402.75 for the day, a gain of 1.31% for the day session. The total traded volume was 809,803. The stocks close on the previous trading day was $397.56.

Regeneron Pharmaceuticals, Inc. is an integrated biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates under development in other areas, including hypercholesterolemia, oncology, rheumatoid arthritis (RA), asthma and atopic dermatitis. The Companys marketed products include EYLEA (aflibercept) injection, ZALTRAP (ziv-aflibercept) injection for intravenous infusion and ARCALYST (rilonacept) injection for subcutaneous use. The Company has 17 product candidates in clinical development. Its product candidates consist of two trap-based clinical programs and 15 human monoclonal antibody product candidates. The Company has generated each of the antibodies using its VelocImmune technology.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.